91 results about "Movement disorders" patented technology

A peripheral nerve stimulator to stimulate a peripheral nerve to treat essential tremor and other movement disorders, as well as overactive bladder, cardiac dysfunction and neurotransmitter dysfunction is provided. The peripheral nerve stimulator can be a noninvasive surface stimulator to provide multi-modal optimized therapy. Stimulation can be vibrational, electromechanical, thermal, radiant, electrical, magnetic, electromagnetic, light, mechanical, chemical, thermal, ultrasonic, radiofrequency (RF), acoustic, infrared, ultraviolet, x-ray, and / or microwave. Stimulation can be delivered using an open loop system and / or a closed loop system with feedback. Stimulation can be to one site or multiple sites.

The invention discloses a weight loss gait test evaluation and training device and method, and the device comprises a weight loss control module which is used for weighing the weight of a user in real time and automatically adjusting the air pressure of an air bag according to a set weight loss proportion; the gait information acquisition module is used for synchronously acquiring plantar pressure distribution, lower limb joint kinematics parameters and double-view video data; the multi-modal gait evaluation grading model module is used for processing plantar pressure distribution, lower limb joint kinematics parameters and double-view video data and outputting lower limb dyskinesia grades; and the training scheme generation model module is used for automatically generating a training scheme including a weight reduction proportion, a treadmill speed, single exercise time and training times per week according to the lower limb dyskinesia level and the personal information of the user.

The invention provides therapeutic methods, pharmaceutical compositions, and unit dose formulations for treating movement disorders, such as using a muscarinic acetylcholine receptor inhibitor in combination with a muscarinic acetylcholine receptor activator to treat dystonia. In some aspects, the invention provides a method of treating a movement disorder in a patient, where the method comprises administering to a patient in need thereof (i) a muscarinic acetylcholine receptor inhibitor in an amount effective to treat the movement disorder and (ii) a muscarinic acetylcholine receptor activator in an amount effective to reduce the frequency and / or magnitude of at least one side effect of the muscarinic acetylcholine receptor inhibitor, to thereby treat the movement disorder.

To provide a motion analysis device that can be used for evaluating a motor function or motion disorder.SOLUTION: A motion analysis device (20) includes elbow flexure ratio calculation means (222) for calculating an elbow flexure ratio of an upper limb in elevation exercise which is expressed by an expression (1) or an expression (2) from respective three-dimensional coordinate data of the shoulder, elbow, and hand of a person to be evaluated when the person to be evaluated is in upper limb elevation exercise. In the expression (2), SH represents a vector from the shoulder to the hand, SE represents a vector from the shoulder to the elbow, and EH represents a vector from the elbow to the hand.SELECTED DRAWING: Figure 1

Described herein are steroids of Formula (I):and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The invention discloses an exoskeleton robot rehabilitation parameter dynamic evaluation method and system based on gait quantitative analysis, and the method achieves the precise matching of a closest reference standard for a patient through an intelligent reference matching algorithm based on the dynamic reference matching technology of height and weight, and achieves the personalized adaptation of an evaluation reference. Misjudgment caused by an evaluation mode only depending on doctor experience is avoided, rehabilitation training parameters better fit actual physiological features of a patient, meanwhile, through a multi-dimensional gait scoring model, angle deviation analysis and bilateral coordination evaluation are fused, left and right joint activities are paired and defined, and a bilateral limb activity difference value is calculated, so that the rehabilitation training accuracy is improved. The asymmetric dyskinesia of a hemiplegic patient is accurately identified, a quantitative basis is provided for making a rehabilitation scheme, accurate judgment is performed according to own data characteristics of different users, and a rehabilitation treatment scheme is customized for the users by using quantitative data reference, so that the consistency and accuracy of the rehabilitation effect are ensured.

Disclosed are a dual regulator for mGluR5 and HDAC6 and use thereof. More specifically, disclosed are a compound that simultaneously regulates mGluR5 and HDAC6, and use thereof as a therapeutic agent for movement disorders.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

Treatments of neuromuscular conditions, activity-induced muscle damage, metabolic myopathies, and movement disorders with compositions comprising 2-((5-fluoropyridin-3-yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl)pyridazin-3(2H)-one (Compound 1), as well as solid forms of Compound 1, and pharmaceutical compositions of Compound 1, and kits of Compound 1, are described herein.

Devices, systems, and techniques for monitoring patient movements using remote sensors are described herein. For example, processing circuitry may be configured to control a user interface of a mobile computing device to deliver a notification to a user to perform at least one movement test and receive, via the user interface, user input requesting to begin the at least one movement test. Responsive to receiving the user input, the processing circuitry can control the user interface to display a set of instructions for the at least one movement test during a period of time, control a camera of the mobile computing device to generate image data of the patient corresponding to the at least one movement test during the period of time, and determine, based on the image data, one or more metrics corresponding to the at least one movement test.

To provide compositions and methods for treating and preventing cognitive impairment, movement disorders, chronic pain, depression, decreased appetite, and addiction.SOLUTION: Also provided are methods for the diagnosis and monitoring of cognitive impairment, movement disorders, chronic pain, depression, decreased appetite, addiction, and other conditions such as convulsion or seizure. These compositions comprise fatty acid compounds and salts thereof which may be administered either alone, in combination with other medicaments, or as part of various treatment regimens. The provided compositions are effective for modulating markers, including, but not limited to, behavior associated with cognitive impairment, movement disorders, chronic pain, depression, decreased appetite, opiate addiction, and other related conditions. Methods for administering the compositions are also provided.SELECTED DRAWING: Figure 1

A peripheral nerve stimulator to stimulate a peripheral nerve to treat essential tremor and other movement disorders, as well as overactive bladder, cardiac dysfunction and neurotransmitter dysfunction is provided. The peripheral nerve stimulator can be a noninvasive surface stimulator to provide multi-modal optimized therapy. Stimulation can be vibrational, electromechanical, thermal, radiant, electrical, magnetic, electromagnetic, light, mechanical, chemical, thermal, ultrasonic, radiofrequency (RF), acoustic, infrared, ultraviolet, x-ray, and / or microwave. Stimulation can be delivered using an open loop system and / or a closed loop system with feedback. Stimulation can be to one site or multiple sites.

The invention discloses a calcaneal fracture three-dimensional traction reduction device, and relates to the technical field of medical instruments, the calcaneal fracture three-dimensional traction reduction device comprises a base, a supporting pad is fixedly arranged at the top of the base, a side plate is fixedly arranged on the side wall of the supporting pad, and a horizontal plane moving mechanism is rotatably arranged at the top in the base. Through the arrangement of an arc plate, an arc block, a rotating seat and an arc limiting groove, a connecting rod and a rotating ring are driven to drive a calcaneal fracture part of a patient to rotate synchronously aiming at the rotation of the calf of the patient, so that the traction direction of the patient is always kept consistent, and the whole body is driven to move through the rotation of the calf during movement; the fracture traction part of a patient is prevented from being pulled and painful, small-range movement of the patient can be guaranteed, the comfort of the patient is improved, the traction puncture part of the patient can be prevented from being painful, synchronous adjustment of the traction force direction along with movement is guaranteed, and joint stiffness and movement disorder caused by long-time fixation of the joint are avoided.

Provided are isotopically-labelled Trapidil derivatives useful for the treatment of Parkinson's disease and movement disorders associated with Parkinson's disease. The isotopically-labelled Trapidil derivatives include deuterated Trapidil derivatives. Additionally provided are combination therapies of isotopically-labelled Trapidil derivatives and additional therapeutic agents for the treatment of Parkinson's disease and movement disorders associated with Parkinson's disease.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The present disclosure provides a crystalline form of enantiopure deuterium-enriched bupropion, pharmaceutical compositions, and methods of treating mood disorders, neurological disorders, movement disorders, cardiovascular disorders, metabolic disorders, and other disorders using a crystalline form of enantiopure deuterium-enriched bupropion.

Materials and methods are provided herein for detecting the presence of an autoantibody specific for PDE10A to identify the mammal as having an autoimmune neurological disorder as well as methods and materials for treating an autoimmune neurological disorder. Materials and methods also are provided herein for treating cancer and / or neurological autoimmunity in a mammal using an immune checkpoint inhibitor and detecting the presence of an autoantibody specific for PDE10A to monitor for the development of neurologic complications in the mammal.

The present invention relates to a method of treatment of movement disorders, comprising administering to a patient in need thereof an effective amount of befiradol, wherein the administering step provides an average patient's maximum plasma concentration of befiradol below 15 ng / mL which occurs more than 4 hours post administration, said method minimizing side effects of dizziness and nausea. Sustained release pharmaceutical compositions that can be used according to this method are also described.

A method of treating movement disorders, by administering an effective amount of a psychedelic to an individual having a movement disorder, and treating the movement disorder.

Restless Leg Syndrome (RLS) or Periodic Limb Movement Disorder (PLMD) can be treated using high frequency (HF) electrostimulation. This can include selecting or receiving a subject presenting with RLS or PLMD. At least one electrostimulation electrode can be located at a location associated with at least one of, or at least one branch of, a sural nerve, a peroneal nerve, or a femoral nerve. HF electrostimulation can be delivered to the subject, which can include delivering subsensory, subthreshold, AC electrostimulation at a frequency that exceeds 500 Hz and is less than 15,000 Hz to the location to help reduce or alleviate the one or more symptoms associated with RLS or PLMD. A charge-balanced controlled-current HF electrostimulation waveform can be used.

The present invention provides therapeutic methods, pharmaceutical compositions and unit dose formulations for the treatment of dyskinesia, such as the treatment of muscular dyskinesia using a muscarinic acetylcholine receptor inhibitor in combination with a muscarinic acetylcholine receptor activator.

Provided herein are osmotic dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once-daily basis, the dosage forms provide a favorable pharmacokinetic profile for the active agent indicating treatment efficacy over an extended period of time.

Isotopically labeled trimetazidine derivatives useful for treating Parkinson's disease and movement disorders associated with Parkinson's disease are provided. The isotopically labeled trimetazidine derivatives include deuterated trimetazidine derivatives. In addition, combination therapies of isotopically labeled trimetazidine derivatives and additional therapeutic agents for treating Parkinson's disease and movement disorders associated with Parkinson's disease are also provided.

The application provides application of a TRPML1 specific small molecule inhibitor ML-SI3 in preparation of a drug for treating or preventing brain injury. The application has the following beneficial effects: the TRPML1 specific small molecule inhibitor ML-SI3 can significantly reduce the injury degree of neurons of a brain injury rat; the learning and memory ability of the brain injury rat is improved; the movement disorder of the brain injury rat is improved, and the brain function of a rat after cardiopulmonary resuscitation after cardiac arrest is comprehensively protected; the TRPML1 specific small molecule inhibitor ML-SI3 provides a new drug for brain function protection of a cardiac arrest patient, and has good market value and clinical application prospect.

Described herein are triazalone compounds of Formula (I): and pharmaceutically acceptable salts thereof. Methods of making and using compounds of Formula (I) are also described. Compounds of Formula (I) and pharmaceutically acceptable salts thereof can be useful as adenosine receptor antagonists, for example in the treatment of diseases or conditions mediated by the adenosine receptor, such as cancer, movement disorders, or attention disorders.

The invention provides a limb dyskinesia recognition and active exercise auxiliary control method based on computer vision, and relates to the technical field of exercise rehabilitation engineering. According to the method, the motion image sequence of the upper limbs and / or the lower limbs of the patient is obtained, the multi-joint three-dimensional coordinates are extracted to form the spatial position data, and the joint angles and the angular speeds are calculated to obtain the joint motion state data. Combining with the torque support evidence, identifying joint angle deviation, angular velocity abnormity and compensation behaviors, generating a dyskinesia identification result containing intention intensity and compensation indexes, and determining target auxiliary joint and auxiliary torque output according to the dyskinesia identification result; and active motion auxiliary control is implemented in modes of joint driving assistance, torque compensation, track amplification or lateral force compensation and the like. According to the invention, fine recognition and self-adaptive assistance of dyskinesia can be realized without additional wearable equipment, and the accuracy and safety of rehabilitation training are improved.

The present disclosure provides a crystalline form of enantiopure deuterium-enriched bupropion, pharmaceutical compositions, and methods of treating mood disorders, neurological disorders, movement disorders, cardiovascular disorders, metabolic disorders, and other disorders using a crystalline form of enantiopure deuterium-enriched bupropion.

The present invention provides method of treating a subject afflicted with a movement disorder, comprising administering to the subject a compound having the structure:whereinR1 is —(C2-C12 alkyl), -(alkenyl), -(alkynyl), -(cycloalkyl);R2 is H, halogen, —NO2, —CN, —CF3, —CF2H, —CH2OCH3, —CF2CH3, —CF2OCH3, -(alkyl), -(alkenyl), -(alkynyl), -(cycloalkyl), -(cycloalkylalkyl), -(heteroalkyl), -(heterocycle), -(heterocycloalkyl), -(aryl), -(heteroaryl), -(hydroxyalkyl), -(haloalkyl), -(alkylaryl), —OH, —O-(alkyl), —O-(alkenyl), —O-(alkynyl), —O-(haloalkyl), —O-(aryl), —O-(heteroaryl), —OCF3, SH, —S-(alkyl), —S-(alkenyl), —S-(alkynyl), —S-(aryl), —S-(heteroaryl), —NH2, —NH-(alkyl), —NH-(alkenyl), —NH-(alkynyl), —N-(alkyl)2, NH-(aryl), —NH-(heteroaryl), —CO2H, —CO2-(alkyl), —C(O)—NH2, —C(O)—NH-(alkyl), —C(O)—NH-(aryl), —SO2CH3 or —Si(CH3)3;R3 is —OCH3, —OCH2CH3, —F or —Cl; andR4 is —OCH3, —OCH2CH3 or —SCH3;wherein when R1 is —CH2CH3, R3 is —OCH3, and R4 is —OCH3, then R2 is other than H, —CH3, —CH2CH3, —CH2CH2CH3, —CH(CH3)2, —CH2CH2CH2CH3, —CH2OH, —CH(OH)CH3, —OH, —OCH2CH3, —OCH2CH2CH3, —OCH(CH3)2, —SCH3, —SCH2CH3, —SCH2CH2CH3, —NO2, —NH2, —F, —Cl, —Br or —I,or a pharmaceutically acceptable salt thereof.

The present invention belongs to the technical field of medical diagnosis and treatment evaluation, specifically a movement disorder treatment effect evaluation system based on HD-sEMG and neuron analysis. The present invention induces pathological tremor symptoms in the hands of patients with movement disorders, collects HD-sEMG data of the forearm, and analyzes and evaluates the improvement effect of pathological tremor symptoms in patients with movement disorders before and after DBS treatment; the system includes: a data acquisition platform, which records surface electromyography data of forearm flexors and extensors; a data preprocessing module, which removes noise and baseline drift by filtering to improve signal quality; a motor unit decomposition and identification module, which decomposes and identifies the motor units of forearm flexors and extensors; a micro-neuron characteristic analysis module, which analyzes neuronal discharge characteristics and reflects changes in neural control; by comparing the changes in neuronal characteristics before and after deep brain stimulation treatment, the improvement of tremor symptoms is evaluated, and doctors are assisted in optimizing treatment plans, thereby improving treatment effects and improving patients' quality of life.

This invention discloses a method for Chinese character input combining eye-tracking and P300 technology. The method utilizes the spatial modulation information of the eye-tracking device to select a mode: the eye-tracking device collects the user's visual trajectory in real time, obtaining the coordinates of the user's eye movement points. When the user gazes at the start option, the system detects this intention and generates a command to activate the spelling process. Combining the eye-tracking device and P300 technology, the initials and finals of the Chinese characters are selected. The method then integrates with a Pinyin input method to achieve the function of inputting Chinese characters: after selecting the initials and finals, the user switches to the Pinyin input method, selects the target Chinese character, and thus achieves the Chinese character input function. This invention, combining eye-tracking and P300 technology for Chinese character input, allows users to achieve computer typing functions without taking any action, relying solely on their eyes and brain. Furthermore, the use of a standard Chinese input method's character library enables matching Chinese characters after spelling. This expands the scope of assistive devices for people with movement disorders beyond computer devices themselves, and has significant practical implications.